---

$4.84

+0.0900 ( +1.90% ) 178.9K

Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.

Type: All Buy Sale Start date: End date: Filter Reset

Date	Type	Amount Purchased	Purchaser
2025-09-02	Buy	5255106.00	ORBIMED ADVISORS LLC
2025-09-02	Buy	5255106.00	Ashiya Mona
2024-10-08	Buy	36500.00	Schreiber Taylor
2024-07-01	Buy	5416.00	Brous Tyler
2024-06-26	Buy	14400.00	Schreiber Taylor
2024-06-21	Sale	-27700.00	Redmile Group, LLC
2024-06-21	Sale	-27700.00	Lee Michael Stewart
2024-05-14	Sale	-967.00	Stout Stephen
2024-01-16	Sale	-49050.00	Stout Stephen
2024-01-16	Sale	-33425.00	Shukla Abhinav A.